NCT05689684View on ClinicalTrials.gov

Arabinoxylan-oligosaccharides (AXOS) for the Management of Type-2 Diabetes

NACompletedINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

November 7, 2022

Primary Completion Date

October 6, 2023

Study Completion Date

December 31, 2024

Conditions
Diabetes Type 2
Interventions
DIETARY_SUPPLEMENT

AG+XOS+AXOS

4-month parallel randomized controlled study

DIETARY_SUPPLEMENT

Placebo Maltodextrin

4-month parallel randomized controlled study

Trial Locations (1)

221 00

Biomedical Nutrition, Lund University and Department of Endocrinology , Lund University Hospital, Lund

Sponsors

Collaborators (1)

Carbiotix AB
All Listed Sponsors
collaborator

Carbiotix AB

INDUSTRY

collaborator

Skane University Hospital

OTHER

collaborator

Vinnova

OTHER_GOV

lead

Lund University

OTHER

NCT05689684 - Arabinoxylan-oligosaccharides (AXOS) for the Management of Type-2 Diabetes | Biotech Hunter | Biotech Hunter